CD4 and cancer: Studies of TNFR2 expression by lymphocytes have supported the potential use of TNFR2 as a target for therapy in cancer by demonstrating that CD4+ TNFR2+ Tregs were connected to elevated disease progression in malignancy [31,32,33,34,35,36,37,38].